In summary, the results indicate that PCSK9 inhibitors can reduce serum PCSK9, TC, and LDL levels in T2DM rats, with no significant effects on body weight and glycemic metabolism indicators. The gene discussed is PCSK9; the disease is type 2 diabetes mellitus.